Corsair Pharma, Inc KOL Webinar on the Treatment of Pulmonary Arterial Hypertension
|DATE:||July 8, 2021|
|TIME:||12:00 AM EDT|
About The Event
The webinar will feature a presentation by Key Opinion Leaders (KOLs) Jeremy Feldman, M.D. (Arizona Pulmonary Specialists) and Richard N. Channick, M.D. (David Geffen School of Medicine at UCLA) who will discuss the current treatment landscape and unmet medical need in treating patients with Pulmonary Arterial Hypertension (PAH). Drs. Feldman and Channick will both be available to answer questions following the formal presentations.
Corsair Pharma’s management team will also give an update on their lead product candidate, a prodrug of treprostinil delivered on a proprietary transdermal patch to treat pulmonary arterial hypertension (PAH). The patch is intended to provide continuous and consistent blood levels of treprostinil comparable to an infusion pump by delivering an inactive prodrug, which crosses the skin, enters the blood, and converts rapidly to treprostinil in the liver. Via this route of administration, a treprostinil prodrug has the potential to provide the efficacy and fast titration of parenteral, the convenience of oral, and a more favorable side effect profile than currently available alternatives. Corsair is also exploring expansion opportunities into other forms of pulmonary hypertension. They have a strategic partnership with United Therapeutics, the market leader in PAH therapies